Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH

<p>Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially differentiated safety profile Results support DNTH103’s best-in-class potential to be the first subcutaneous, self-administered injection dosed as infrequently as once every two weeks to treat a range of autoimmune disorders Company plans to initiate multiple [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/dianthus-therapeutics-announces-positive-top-line-phase-1-data-and-debuts-trading-on-nasdaq-as-dnth/">Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>